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In 2015/16, the influenza season in the United Kingdom 
was dominated by influenza A(H1N1)pdm09 circula-
tion. Virus characterisation indicated the emergence of 
genetic clusters, with the majority antigenically similar 
to the current influenza A(H1N1)pdm09 vaccine strain. 
Mid-season vaccine effectiveness (VE) estimates show 
an adjusted VE of 41.5% (95% confidence interval (CI): 
3.0–64.7) against influenza-confirmed primary care 
consultations and of 49.1% (95% CI: 9.3–71.5) against 
influenza A(H1N1)pdm09. These estimates show levels 
of protection similar to the 2010/11 season, when this 
strain was first used in the seasonal vaccine.
Introduction
The United Kingdom (UK) has had for many years an 
influenza vaccination programme using inactivated 
influenza vaccine targeted at individuals at higher 
risk of severe disease such as the elderly and under 
65-year-olds in a clinical risk group. The 2015/16 influ-
enza season is the third where an intranasally admin-
istered live attenuated influenza vaccine was provided 
to children [1]. This winter has been characterised by 
circulation of mainly influenza A(H1N1)pdm09, with 
evidence of hospitalisations and admissions to the 
intensive care unit (ICU) particularly in younger adults 
15 to 64 years of age [2]. Influenza A(H1N1)pdm09 pre-
viously circulated in the UK in 2013/14, 2012/13 and 
particularly in 2010/11, the first post-pandemic season 
where particular impact was seen in younger adults. 
The 2015/16 season has also seen a large number of 
school and hospital outbreaks with evidence of excess 
all-cause mortality in 15 to 64 year-olds using the 
EuroMoMo standard algorithm [2].
The UK has long-standing systems to measure influ-
enza vaccine effectiveness (VE) in the middle and at 
the end of the season [3,4]. The aims of the present 
study were to provide early season estimates of influ-
enza VE to inform influenza prevention and control 
measures both for the remainder of this season and 
for the World Health Organization (WHO) northern 
hemisphere meeting that was held in February 2016 to 
decide influenza vaccine composition for the forthcom-
ing 2016/17 season.
Methods
Study population and period
Five primary care influenza sentinel swabbing surveil-
lance schemes from England (two schemes), Scotland, 
Wales and Northern Ireland provided data. Information 
on the Royal College of General Practitioners (RCGP) 
Research and Surveillance Centre (RSC), Public Health 
England (PHE) Specialist Microbiology Network (SMN), 
Public Health Wales, Public Health Agency (PHA) of 
Northern Ireland and Health Protection Scotland (HPS) 
schemes have been provided in earlier publications [4].
The time of investigation ran from 1 October 2015 to 
22 January 2016. Patients were swabbed during their 
consultation, with verbal consent. Cases were defined 
as patients presenting to a general practitioner (GP) 
in a participating practice with an acute influenza-like 
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illness (ILI) who tested positive for influenza A or 
B viruses by real-time PCR. Controls were individu-
als presenting with ILI in the same period who tested 
negative for influenza. ILI was defined as an individual 
presenting in primary care with an acute respiratory 
illness with physician-diagnosed fever or complaint of 
feverishness. 
A standardised form was completed by the GP during 
the consultation. Demographic, epidemiological and 
clinical information was collected from participants, 
including date of birth, sex, defined underlying clinical 
risk group, date of specimen collection, date of onset of 
respiratory illness, and influenza vaccination status for 
the 2015/16 season with vaccination dates and route 
of administration (injection/intranasal). It was also 
recorded (in England, Scotland and Northern Ireland) 
whether the patient was resident in an area where a 
primary school-age programme was in operation.
Laboratory methods
Sentinel samples from the GP surveillance networks 
were sent to the national laboratories as previously 
described [4]. Laboratory confirmation was undertaken 
at all sites using comparable real-time PCR methods 
capable of detecting circulating influenza A and influ-
enza B viruses and other respiratory viruses [5,6]. In 
addition, hospital diagnostic laboratories submitted 
samples in which influenza virus had been detected 
to the reference laboratories from a selection of cases 
(including severe cases and vaccinated cases) for fur-
ther strain characterisation. Influenza viruses from all 
sources (both sentinel and non-sentinel) were isolated 
from PCR-positive samples in Madin-Darby canine kid-
ney epithelial (MDCK) cells or MDCK cells containing 
the cDNA of human 2,6-sialtransferase (SIAT1) cells as 
previously described [7,8]. 
Influenza A(H1N1)pdm09 virus isolates with a haemag-
glutination titre ≥ 40 were characterised antigenically 
using post-infection ferret antisera in haemagglutina-
tion inhibition (HI) assays, with turkey red blood cells 
[9]. Reference virus strains used for HI assays included 
A/California/7/2009 (vaccine strain) grown in embryo-
nated chicken eggs, and other A(H1N1)pdm09 England 
strains were grown in embryonated chicken eggs or 
tissue culture cells. The fold difference between the 
homologous HI titre for egg-grown A/California/7/2009 
and the HI titre for each clinical isolate was calculated 
to determine antigenic similarity of clinical isolates to 
the vaccine strain. 
Nucleotide sequencing of the haemagglutinin (HA) 
gene of a subset of influenza A(H1N1)pdm09 viruses 
selected to be representative of the range of the 
patients’ age, date of sample collection, geographical 
location and antigenic characterisation of the virus iso-
late, if performed, was undertaken (primer sequences 
available on request), and phylogenetic trees were 
constructed with a neighbour-joining algorithm avail-
able in the Mega 6 software (http://www.megasoft-
ware.net) [10]. HA sequences from reference strains 
used in the phylogenetic analysis were obtained from 
the EpiFlu database of the Global Initiative on Sharing 
Avian Influenza Data (GISAID) (Table 1).
The HA sequences from England obtained in this study, 
which were also used in the phylogenetic analysis, 
were deposited in GISAID under the following acces-
sion numbers: EPI679151, EPI679186, EPI679213, 
EPI679221, EPI679245, EPI679266, EPI679300, 
EPI679313, EPI711775, EPI711780, EPI711788, 
EPI711796, EPI711804, EPI711812, EPI711820, 
EPI711828, EPI711834, EPI711842, EPI711850, 
EPI711858, EPI711866, EPI711873, EPI711881, 
EPI711888, EPI711893, EPI711901, EPI711909, 
EPI711917, EPI711925, EPI711930, EPI711938, EPI711943, 
EPI711951, EPI711959, EPI711967, EPI711975, EPI711983, 
EPI711991, EPI711996, EPI712002, EPI712007, 
EPI712012, EPI712020, EPI712028, EPI712036, 
EPI712044, EPI712052, EPI712060, EPI712068, 
EPI712076, EPI712084, EPI712092, EPI712100, 
EPI712108, EPI712116, EPI712121, EPI712129, EPI712137, 
EPI712142, EPI712150, EPI712166, EPI712167, EPI712168, 
EPI712169, EPI712170, EPI712171, EPI712172, EPI712311.
Figure 1
Specimen inclusion and exclusion criteria, interim 
2015/16 influenza vaccine effectiveness evaluation, United 
Kingdom, 1 October 2015–22 January 2016 (n = 2,666)
N=2,666 in 
original dataset
Samples included in the 
analysis
N=1,548
Cases 
N=182
Controls
N=1,366
Excluded samples sequentially:
Date of sample prior to 1 Oct 2015 (n=110)
Inﬂuenza status unknown (n=30)
Live attenuated inﬂuenza vaccine strain (n=1)
Vaccination status unknown (n=120)
Date of vaccination not known (n=86)
Vaccination <14 days from onset (n=94)
Date of onset unknown (n=94)
Swab >7 days after onset or missing (n=583)
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Figure 2
Phylogenetic analysis of full length haemagglutinin gene comparing reference sequences from the GISAID EpiFlu database 
and influenza A(H1N1)pdm09 sequences from patients, United Kingdom, 2015/16 influenza season
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A/England/53640770/2015
A/N.Ireland/60160401/2015
A/N.Ireland/60160403/2015
A/N.Ireland/60160398/2015
A/N.Ireland/60160395/2015
A/England/60180752/2016
A/England/86/2016
A/England/74/2016
A/England/51/2016
A/England/366/2015
A/England/397/2015
A/England/60220032/2016
A/England/388/2015
A/England/442/2015
A/Scotland/60240321/2016
A/England/3/2014
A/Scotland/60180122/2015
A/England/60160121/2016
A/England/390/2015
A/England/375/2015
A/England/400/2015
A/England/377/2015
A/England/55240296/2015
A/England/60120142/2015
A/England/357/2015
A/England/184/2015
A/England/55240293/2015
A/England/55240295/2015
A/England/358/2015
A/England/439/2014
A/England/354/2014
A/England/353/2015
A/England/150/2015
A/England/101/2015
A/England/125/2015
A/England/41/2015
A/England/341/2015
A/England/579/2014
A/England/340/2015
A/South-Africa/3626/2013
A/Estonia/76677/2013
A/Hong-Kong/5659/2012
A/St-Petersburg/27/2011
A/St-Petersburg/100/2011
A/Czech-Republic/32/2011
A/Astrakhan/1/2011
A/Christchurch/16/2010
A/Hong-Kong/2212/2010
A/Hong-Kong/3934/2011
A/England/195/2009
A/California/7/2009
0.002
6B.1
6C
6A
6B
6B.2
S84N, S162N, I216T
K163Q
A256T
E491G
V152T, V173I, D501E
A215G
N129D
R450K
The tree was built using a neighbour-joining algorithm, with vaccine strain A/California/07/2009 selected as the root. Signature amino acid 
substitutions characterising genetic groups are annotated at the root of each cluster. 2015/16 UK samples are highlighted in bold. Sentinel 
samples are highlighted in red.
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Statistical methods
Patients were defined as vaccinated if the date of vac-
cination with the 2015/16 seasonal vaccine was at least 
14 days before onset of illness. Those vaccinated less 
than 14 days before onset of illness and those with 
unknown date of vaccination were excluded. Those with 
unknown date of onset or onset date more than seven 
days before the swab was taken were also excluded.
VE was estimated by the test-negative case control 
design. In that design, VE is calculated using odds 
ratios (OR) as 1−(OR) obtained using multivariable 
logistic regression models with influenza A PCR results 
(influenza B numbers were too small to examine) and 
seasonal vaccination status as the linear predictor. VE 
was also calculated separately for influenza A(H1N1)
pdm09. In the analyses evaluating VE for a specific 
type or strain, those positive for other virus types 
were excluded from the analysis. For this mid-season 
analysis, we fixed the variables for adjusted estimates 
based on past seasons as age (coded into standard 
age groups, < 5, 5–17, 18–44, 45–64 and ≥ 65 years), 
Table 1
Influenza A(H1N1)pdm09 haemagglutinin sequences obtained from GISAID used in the phylogenetic analysis
Virus isolate
Segment ID/
Accession number
Country
Collection date 
(year-month-day)
Originating laboratory Submitting laboratory
A/Astrakhan/1/2011 EPI319590 Russian Federation 2011-Feb-28
WHO National 
Influenza Centre, 
Saint Petersburg, 
Russian Federation
National Institute for 
Medical Research, 
London, UK
A/St. Petersburg/27/2011 EPI319527 Russian Federation 2011-Feb-14
WHO National 
Influenza Centre, 
Saint Petersburg, 
Russian Federation
National Institute for 
Medical Research, 
London, UK
A/England/3/2014 EPI503206 United Kingdom 2014-Jan-08
Microbiology Services 
Colindale, Public 
Health England, 
London, UK
National Institute for 
Medical Research, 
London, UK
A/Estonia/76677/2013 EPI466545 Estonia 2013-Mar-13
Health Protection 
Inspectorate, Tallin, 
Estonia
National Institute for 
Medical Research, 
London, UK
A/Hong Kong/5659/2012 EPI390473 Hong Kong (SAR) 2012-May–21
Government Virus 
Unit, Hong Kong (SAR)
National Institute for 
Medical Research, 
London, UK
A/Hong Kong/3934/2011 EPI326206 Hong Kong (SAR) 2011-Mar-29
Government Virus 
Unit, Hong Kong (SAR)
National Institute for 
Medical Research, 
London, UK
A/Hong Kong/2212/2010 EPI279895 Hong Kong (SAR) 2010-Jul-16
Government Virus 
Unit, Hong Kong (SAR)
National Institute for 
Medical Research, 
London, UK
A/Czech Republic/32/2011 EPI319447 Czech Republic 2011-Jan-18
National Institute of 
Public Health, Prague, 
Czech Republic
National Institute for 
Medical Research, 
London, UK
A/England/195/2009 EPI178507 United Kingdom 2009-Apr-28
Microbiology Services 
Colindale, Public 
Health England, 
London, UK
National Institute for 
Medical Research, 
London, UK
A/St. Petersburg/100/2011 EPI316435 Russian Federation 2011-Mar-14
Russian Academy of 
Medical Sciences, 
Saint Petersburg, 
Russian Federation
Centers for Disease 
Control and Prevention, 
Atlanta, US
A/South Africa/3626/2013 EPI577031 South Africa 2013-Jun-06
National Institute for 
Medical Research, 
London, UK
Centers for Disease 
Control and Prevention, 
Atlanta, US
A/Christchurch/16/2010 EPI280344 New Zealand 2010-Jul-12
WHO Collaborating 
Centre for Reference 
and Research on 
Influenza, Melbourne, 
Australia
Centers for Disease 
Control and Prevention, 
Atlanta, US
A/California/07/2009 EPI177294 United States 2009-Apr-09
Naval Health Research 
Center, San Diego, US
Centers for Disease 
Control and Prevention, 
Atlanta, US
GISAID: Global Initiative on Sharing All Influenza Data; SAR: Special Administrative Regions of the People's Republic of China; UK: United 
Kingdom; US: United States; WHO: World Health Organization.
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sex, surveillance scheme (RCGP, SMN, HPS, Wales, 
Northern Ireland), residence in an area where a primary 
school-age programme operated and date of sample 
collection (month). All statistical analyses were car-
ried out in Stata version 13 (StataCorp, College Station, 
Texas).
Results
The reasons for study inclusion and exclusion are out-
lined in Figure 1.
Of the 2,666 swabbed individuals, 1,548 individuals 
were included in the study. Their details were strati-
fied according to the swab result. There were a total 
of 1,366 controls, 20 influenza B detections, 152 influ-
enza A(H1N1)pdm09 detections, 3 influenza A(H3N2) 
detections and nine influenza A(unknown) detections. 
Influenza A(H1N1)pdm09 positivity rates were high-
est by age in younger than five years (16.8%) and in 
18 to 44 year-olds (10.9%), by vaccine status in those 
who were unvaccinated (11.1%) compared with vacci-
nated (5.6%), and in non-pilot (14.1%) compared with 
pilot areas (6.3%). Overall positivity rates differed sig-
nificantly by age group (highest in <5 year-olds), sex 
(higher in males), risk group (higher in those without 
a risk factor), month (highest in January), scheme, vac-
cination status (highest in unvaccinated) and area of 
primary school-age programme (highest in non-pilot 
areas) (Table 2).Numbers and row percentages (to indi-
cate positivity rates) are shown.
Influenza A(H1N1)pdm09 strain 
characterisation from sentinel and non-sentinel 
samples
Since the start of the 2015/16 winter influenza season 
in week 40 2015, the PHE Respiratory Virus Unit has 
characterised a total of 274 influenza A(H1N1)pdm09 
viruses from all sources; 103 genetically (of which 
nine (9%) from sentinel sources), 210 antigenically (of 
which 46 (22%) sentinel sources) and 39 both antigeni-
cally and genetically (of which three (8%) from sentinel 
sources). 
The A(H1N1)pdm09 viruses genetically character-
ised to date all belonged in the genetic subgroup 6B 
(Figure 2), which had been the predominant genetic 
subgroup in the 2014/15 season. Some heterogeneity 
has been seen in HA of the current season’s A(H1N1)
pdm09 viruses, with some genetic subgroups becom-
ing evident: the HA genes of more than 85% of A(H1N1)
pdm09 viruses fell into genetic cluster 6B.1, charac-
terised by the amino acid changes S84N, S162N (with 
gain of a potential glycosylation site) and I216T, with 
a subset in this cluster having the substitution A215G. 
Less than 10% of viruses fell into a second emerging 
cluster (6B.2), and had the amino acid substitutions 
V152T, V173I, E491G and D501E in the HA gene, or a 
third minor cluster with substitutions N129D, R450K 
and E491G. A few viruses from this season did not 
show any of these changes or have substitution S84N 
alone, and clustered with A(H1N1)pdm09 viruses from 
season 2014/15 (6B subgroup).
Of 210 viruses analysed by HI assay using ferret post-
infection sera, more than 90% were antigenically simi-
lar to the A/California/7/2009 northern hemisphere 
2015/16 A(H1N1)pdm09 vaccine strain. In the period 1 
October to 30 November 2015, 6% (2/32) of isolates 
had an eightfold or greater reduction in reactivity to 
antiserum raised to egg-grown A/California/7/2009 
virus, compared with 11% (19/178) that had an eight-
fold or greater reduction in the period 1 December 2015 
to 22 January 2016. 
Model fitting for vaccine effectiveness 
estimation
The variables included in the multivariable model (age 
group, sex, month of sample collection, surveillance 
scheme and primary school-age programme area) were 
all significantly associated with swab positivity and 
were confounders for the vaccine effects (changed esti-
mates by more than 5%) with the exception of primary 
school-age programme area. Information on risk group 
was missing for 53 samples (3.4%) and as in previous 
seasons’ analyses [4] was not included in the final 
model.
Vaccine effectiveness estimates against influenza 
A(H1N1)pdm09, influenza A (all types) and all influenza 
are shown in Table 3. It was not possible to estimate 
effectiveness against influenza A(H3N2) or influenza 
B due to inadequate sample number. The adjusted VE 
of influenza vaccine against any influenza was 41.5% 
(95% confidence interval (CI): 3.0–64.7) and was very 
similar for A(H1N1)pdm09 at 49.1% (95% CI: 9.3–71.5). 
Discussion
In a season dominated by circulation of influenza 
A(H1N1)pdm09, we found an overall VE of 41.5% in 
preventing laboratory-confirmed influenza infection 
resulting in a primary care consultation; it was 49.1% 
specifically against A(H1N1)pdm09, reflecting the fact 
that A(H1N1)pdm09 was the dominant circulating strain 
at this stage of the season. We also found some early 
evidence of circulation of A(H1N1)pdm09 genetic vari-
ants, but with no evidence of loss of effectiveness of 
the 2015/16 vaccine.
The UK, together with other European Union Member 
States, the United States, Canada and Australia has 
well established systems to generate interim estimates 
of seasonal influenza VE. These early results are used 
to optimise in-season control and prevention meas-
ures, to inform other countries before their influenza 
season and to contribute to the WHO deliberations 
on the influenza vaccine composition for the north-
ern hemisphere. The UK, as other countries in Europe, 
has experienced a season dominated by circulation of 
influenza A(H1N1)pdm09 with reports of increases in 
hospitalisations and ICU admissions mainly in younger 
adults [11]. Although concerns have been expressed 
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about a possible increase in virulence, the epidemio-
logical observations are consistent with earlier seasons 
in the UK dominated by circulation of A(H1N1)pdm09, in 
particular in 2010/11, the first post-pandemic season, 
but also to a lesser extent in 2012/13 and 2013/14.
Although evidence of heterogeneity has been seen in 
the HA gene of A(H1N1)pdm09 viruses genetically char-
acterised from all sources to date this season, more 
than 90% of the 210 viruses analysed by HI assays were 
antigenically similar to the A/California/7/2009 north-
ern hemisphere 2015/16 (H1N1)pdm09 vaccine strain, 
suggesting little change in the antigenic properties 
Table 2
Details for influenza A and B cases (n = 182) and controls (n = 1,366), United Kingdom, 1 October 2015–22 January 2016 
Control 
(n = 1,366)
Influenza Ba 
(n = 20)
A(H1N1)a 
(n = 152)
A(H3N2) 
(n = 3)
A (unknown) 
(n = 9)
p valueb
Age 
0.001
< 5 163 (83.2%) 2 (1.0%) 33 (16.8%) 0 (0.0%) 0 (0.0%)
5–17 193 (91.9%) 1 (0.5%) 16 (7.6%) 0 (0.0%) 0 (0.0%)
18–44 502 (86.6%) 12 (2.1%) 63 (10.9%) 0 (0.0%) 3 (0.5%)
45–64 315 (88.0%) 4 (1.1%) 32 (8.9%) 2 (0.6%) 5 (1.4%)
≥ 65 192 (95.0%) 1 (0.5%) 7 (3.5%) 1 (0.5%) 1 (0.5%)
Missing 1 (50.0%) 0 (0.0%) 1 (50.0%) 0 (0.0%) 0 (0.0%)
Sex 
0.002
Female 840 (90.3%) 8 (0.9%) 73 (7.8%) 2 (0.2%) 7 (0.8%)
Male 522 (85.2%) 12 (2.0%) 78 (12.7%) 1 (0.2%) 2 (0.3%)
Missing 4 (80.0%) 0 (0.0%) 1 (20.0%) 0 (0.0%) 0 (0.0%)
Surveillance scheme 
< 0.001
Northern Ireland 33 (63.5%) 4 (7.7%) 9 (17.3%) 0 (0.0%) 6 (11.5%)
RCGP 540 (87.8%) 4 (0.7%) 69 (11.2%) 2 (0.3%) 0 (0.0%)
SMN 58 (75.3%) 1 (1.3%) 18 (23.4%) 0 (0.0%) 0 (0.0%)
Scotland 701 (92.8%) 10 (1.3%) 42 (5.6%) 1 (0.1%) 3 (0.4%)
Wales 34 (69.4%) 1 (2.0%) 14 (28.6%) 0 (0.0%) 0 (0.0%)
Risk group 
< 0.001
No 908 (86.5%) 17 (1.6%) 119 (11.3%) 2 (0.2%) 6 (0.6%)
Yes 414 (93.0%) 3 (0.7%) 25 (5.6%) 1 (0.2%) 2 (0.4%)
Missing 44 (83.0%) 0 (0.0%) 8 (15.1%) 0 (0.0%) 1 (1.9%)
Onset to swab 
0.400
0–1 days 145 (86.3%) 0 (0.0%) 21 (12.5%) 0 (0.0%) 2 (1.2%)
2–4 days 713 (87.7%) 12 (1.5%) 84 (10.3%) 3 (0.4%) 3 (0.4%)
5–7 days 508 (89.6%) 8 (1.4%) 47 (8.3%) 0 (0.0%) 4 (0.7%)
Vaccination status 
0.013
Unvaccinated 1,055 (87.0%) 16 (1.3%) 135 (11.1%) 2 (0.2%) 7 (0.6%)
Vaccinated (14–91 days ago) 280 (92.7%) 3 (1.0%) 17 (5.6%) 1 (0.3%) 1 (0.3%)
Vaccinated(> 91 days ago) 31 (93.9%) 1 (3.0%) 0 (0.0%) 0 (0.0%) 1 (3.0%)
Primary school-age programme area 
< 0.001
No 594 (84.7%) 6 (0.9%) 99 (14.1%) 2 (0.3%) 0 (0.0%)
Yes 768 (91.1%) 14 (1.7%) 53 (6.3%) 1 (0.1%) 9 (1.1%)
Missing 4 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Month of event 
< 0.001
October 300 (98.7%) 1 (0.3%) 1 (0.3%) 1 (0.3%) 1 (0.3%)
November 380 (96.4%) 5 (1.3%) 7 (1.8%) 2 (0.5%) 0 (0.0%)
December 446 (85.9%) 5 (1.0%) 67 (12.9%) 0 (0.0%) 1 (0.2%)
January 240 (72.5%) 9 (2.7%) 77 (23.3%) 0 (0.0%) 7 (2.1%)
RCGP: Royal College of General Practitioners’ Research and Surveillance Centre scheme; SMN: Public Health England Specialist Microbiology 
Network.
a Two people tested positive for both influenza B and A(H1N1)pdm09.
 b Positive vs negative for influenza.
Numbers and row percentages (to indicate positivity rates) are shown.
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of circulating strains. Similar observations have been 
reported from other European countries [11]. The full 
picture of virological genetic variation requires further 
detailed analysis, which is not possible at this stage of 
the winter season.
In support of the antigenic characterisation findings, 
we demonstrate that the influenza vaccine has been 
effective in preventing laboratory-confirmed primary 
care consultations this season. The adjusted VE against 
all influenza for all age groups was very similar to that 
against influenza A(H1N1)pdm09 reflecting the fact 
that A(H1N1)pdm09 has been the dominant circulating 
virus strain this season. Indeed, the result is not sig-
nificantly different to that observed for the UK mid-sea-
son estimate in 2010/11, when A(H1N1)pdm09 was the 
dominant circulating strain with an estimate against 
A(H1N1)pdm09 of 51% (95% CI 29 to 66%) [12], and in 
2012/13 with an end of season estimate of 73% (95% 
CI: 37 to 89) [4]. The results were also not significantly 
different from the VE against influenza A(H1N1)pdm09 
of 44.2% (95% CI: −3.1 to 69.8%) recently reported 
for the current season by the European I-MOVE net-
work [13] and the recent estimate from Canada of 64% 
(95% CI: 44–77%) [14]. The lack of apparent antigenic 
and epidemiological vaccine mismatch at this stage is 
encouraging. 
Nonetheless, it is important to highlight lack of preci-
sion in our estimate: the lower 95% CI was 3% and the 
upper CI was 65%, indicating a large range of uncer-
tainty, although we can say with confidence that the 
influenza vaccine has been effective so far this season. 
Furthermore, this mid-season analysis was done at a 
time when activity was still increasing and does not 
preclude the possibility to that there may be changes 
in the dominant circulating strain, with potential impli-
cations for the vaccine effectiveness. These limitations 
will be addressed in the end-of-season analysis which 
will also include stratification by age group and type of 
vaccine, in particular for children.
Finally, the results outlined in this paper have contrib-
uted to the recent global assessment for the coming 
season’s influenza vaccine composition: the WHO rec-
ommended that the vaccine for the 2016/17 northern 
hemisphere winter should continue to include the A/
California/7/2009 vaccine strain [15].
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